Designer benzodiazepines: new challenges and treatment options

Peter D. Maskell, Nathan E. Wilson

    Research output: Chapter in Book/Report/Conference proceedingChapter


    New Psychoactive Substance (NPS) benzodiazepines (AKA designer benzodiazepines) emerged in Europe around 2007, but were first detected and identified in death cases in 2010 in the USA (Bailey et al. 2010) and 2011 in the UK (Maskell et al. 2011a). Since the first NPS benzodiazepines emerged another 20 are being monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), leading to concern that the abuse of NPS benzodiazepines may become a significant global problem. This chapter looks at NPS benzodiazepines, their pharmacology, potency, prevalence, use, abuse, potential poly-pharmacy, risk of hospitalisation, detection in the clinical setting and finally treatment of overdose.
    Original languageEnglish
    Title of host publicationHandbook of novel psychoactive substances
    Subtitle of host publicationwhat clinicians should know about NPS
    EditorsOrnella Corazza, Andrew Roman-Urrestarazu
    Number of pages22
    ISBN (Electronic)9781315158082
    ISBN (Print)9781138068308, 9781138068292
    Publication statusPublished - 19 Oct 2018


    Dive into the research topics of 'Designer benzodiazepines: new challenges and treatment options'. Together they form a unique fingerprint.

    Cite this